Our President and CEO John Lu was recently interviewed by IMAPAC on key developments, technologies and challenges in Asia's Cell and Gene Therapy Industry. You can find the full interview in the PDF attached.
The design of HebeCell’s 3D NK cell manufacture platform mimics lymph node environments of NK cell development in vivo. Compared to other currently available systems, our platform has 6 major technical advantages.
As our understanding of stem cell biology surges forward, new investigational therapies are rapidly advancing towards and through clinical trials. This special Toronto event “From Stem Cell Biology to New Therapies” will highlight current clinical applications of stem cell therapies. The program features world-renowned leaders in translational research from academia and industry, and will include an interactive panel that will discuss the regulatory challenges of translational stem cell research.